Vol. 6 No. 8 (2026): August
Reimbursement Reviews

Nipocalimab (Imaavy)

decorative image of the issue cover

Published August 6, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses nipocalimab (Imaavy), 300 mg per 1.62 mL and 1,200 mg per 6.5 mL solution, for IV use.
  • Indication: As an add-on to standard therapy for the treatment of gMG in adult and adolescent patients aged 12 years and older who are anti-AChR or anti-MuSK antibody positive.